Virginia Braman Selected Research

1-(5-hydroxyhexyl)-3,7-dimethylxanthine

7/2016	A First-in-Patient, Multicenter, Double-Blind, 2-Arm, Placebo-Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP-499, in Chronic Kidney Disease.
7/2014	Quantitative analyses of CTP-499 and five major metabolites by core-structure analysis.
1/2013	A Randomized Phase I Evaluation of CTP-499, a Novel Deuterium-Containing Drug Candidate for Diabetic Nephropathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Virginia Braman Research Topics

Disease

2	Diabetic Nephropathies (Diabetic Nephropathy) 07/2014 - 01/2013
1	Alopecia Areata 01/2022
1	Cystic Fibrosis (Mucoviscidosis) 01/2017
1	Chronic Renal Insufficiency 07/2016
1	Gingivitis 02/2002

Drug/Important Bio-Agent (IBA)

3	Pharmaceutical PreparationsIBA 01/2017 - 01/2013
3	1-(5-hydroxyhexyl)-3,7-dimethylxanthineIBA 07/2016 - 01/2013
1	Janus KinasesIBA 01/2022
1	Janus Kinase InhibitorsIBA 01/2022
1	ivacaftor drug combination lumacaftorIBA 01/2017
1	ivacaftorIBA 01/2017
1	lumacaftorIBA 01/2017
1	AngiotensinsIBA 07/2014
1	diethylstilbestrol monophosphate (PDES)IBA 07/2014
1	DeuteriumIBA 01/2013
1	HistatinsIBA 02/2002

Therapy/Procedure

1	Therapeutics 01/2017